Arizona doctors and hospitals lose immunity from COVID negligence lawsuits, court rules
Sept 15th, 2025
The Arizona Supreme Court has ruled that state lawmakers acted illegally when they voted to immunize doctors and hospitals from negligence claims during the COVID pandemic.
In a split decision on Sept. 12, the justices voided a 2021 statute that was designed to provide liability protection for medical professionals dealing with novel diseases with no known treatment. Lawmakers said they wanted to ensure that doctors and hospitals would continue to treat patients amid the pandemic without the fear of lawsuits.
Read the full article here
Fauci Told Colleagues to Delete COVID-Related Communications, Emails Show
Sept 11th, 2025
The email directives, which may violate federal law, contradict Dr. Anthony Fauci’s congressional testimony last year, when he repeatedly denied deleting official records or engaging in “attempts to obstruct … the release of public documents.” Sen. Rand Paul called on Fauci to testify before Congress.
Read the full article here
FDA Launches Crackdown on Deceptive Drug Advertising
September 9th, 2025
The U.S. Department of Health and Human Services and the Food and Drug Administration today announced sweeping reforms to rein in misleading direct-to-consumer pharmaceutical advertisements. Today, the FDA is sending thousands of letters warning pharmaceutical companies to remove misleading ads and issuing approximately 100 cease-and-desist letters to companies with deceptive ads.
In addition to enforcing existing law, the FDA is initiating rulemaking to close the “adequate provision” loophole created in 1997, which drug companies have used to conceal critical safety risks in broadcast and digital ads, fueling inappropriate drug use and eroding public trust.
“Pharmaceutical ads hooked this country on prescription drugs,” Health and Human Services Secretary Robert F. Kennedy, Jr. said. “We will shut down that pipeline of deception and require drug companies to disclose all critical safety facts in their advertising. Only radical transparency will break the cycle of overmedicalization that drives America’s chronic disease epidemic.”
The FDA is concerned patients are not seeing a fair balance of information about drug products. This concern is magnified when serious risks are not clearly presented, or the information is too difficult for seniors to read or hear.
“For far too long, the FDA has permitted misleading drug advertisements, distorting the doctor-patient relationship and creating increased demand for medications regardless of clinical appropriateness,” said FDA Commissioner Marty Makary, M.D., M.P.H. “Drug companies spend up to 25% of their budget on advertising. Those billions of dollars would be better spent on lowering drug prices for everyday Americans.”
Americans also live in a new era of social media. An increasing reliance on digital and social media channels, including undisclosed paid influencer promotion, has blurred the lines among editorial content, user-generated media and pharmaceutical advertising, making it increasingly difficult for patients to distinguish between evidence-based information and promotional material.
A 2024 review in the Journal of Pharmaceutical Health Services Research reveals that while 100% of pharmaceutical social media posts highlight drug benefits, only 33% mention potential harms. Moreover, 88% of advertisements for top-selling drugs are posted by individuals and organizations that fail to adhere to the FDA fair balance guidelines.
The stakes surrounding prescription drug ads are high. While these ads can raise awareness of disease states and beneficial therapies, they must also disclose important risks and limitations. Current law requires that advertisements present a fair balance between a product’s risks and benefits; avoid exaggerating benefits; not create a misleading overall impression; properly disclose financial relationships; and include information regarding major side effects and contraindications.
Despite widespread violations, the FDA has been increasingly lax and reactive in its enforcement approach over the last few decades. The FDA used to send more than a hundred warning letters each year, and misleading ads were rare. But over time, enforcement waned and the number of warning letters sent to pharmaceutical companies dropped to one in 2023 and zero in 2024.
The FDA will no longer tolerate such deceptive practices. Going forward, the agency will aggressively deploy its available enforcement tools. The FDA is already implementing AI and other tech-enabled tools to proactively surveil and review drug ads.
The Trump Administration and HHS Secretary Kennedy are committed to restoring transparency, accountability, and trust in health care. By closing loopholes and stepping up enforcement, the FDA will protect patients, safeguard public health and hold the pharmaceutical industry accountable.
Read the full article here
‘Clear Up This Mess’: Trump Demands Big Pharma ‘Justify the Success’ of COVID Shots
September 2nd, 2025
President Donald Trump on Monday announced on Truth Social that manufacturers of COVID-19 vaccines and treatments must immediately make public all data about their products. He suggested drugmakers will have to answer for any problems discovered in the data.
Read the full article here
Paul Offit Kicked Off Key FDA Vaccine Panel
September 2nd, 2025
Dr. Paul Offit, an infectious disease specialist at the Children’s Hospital of Philadelphia and outspoken critic of U.S. Health Secretary Robert F. Kennedy Jr., told Endpoints News in an email today that the FDA did not tell him why he was being dismissed from the agency’s Vaccines and Related Biological Products Advisory Committee.
Read the full article here
EXCLUSIVE: C-130 Pilot Prevails, a ‘Huge Victory for Religious Freedom’ Handed Down from the Air Force
September 2nd, 2025
U.S. Air Force Major Brennan Schilperoort, a C-130 pilot who was grounded, financially penalized, and subjected to religious discrimination for years, has finally secured a measure of justice in his prolonged battle with military leadership.
Read the full article here
